A study protocol for expanding the screening interval of endoscopic screening for gastric cancer based on individual risks: prospective cohort study of gastric cancer screening.

Gastric cancer Helicobacter pylori atrophic gastritis cancer screening endoscopic screening screening interval

Journal

Annals of translational medicine
ISSN: 2305-5839
Titre abrégé: Ann Transl Med
Pays: China
ID NLM: 101617978

Informations de publication

Date de publication:
Dec 2020
Historique:
entrez: 13 1 2021
pubmed: 14 1 2021
medline: 14 1 2021
Statut: ppublish

Résumé

The Japanese government has recommended a 2-year endoscopic screening interval for gastric cancer. However, insufficient resources have constrained participation in endoscopic screening for gastric cancer. One way to avoid endoscopic screening harms and provide equal access is to define the appropriate screening interval. To expand screening interval from more than 2 years for low-risk group, a single-arm cohort of endoscopic screening started. At the baseline screening, the participants underwent endoscopic screening for gastric cancer, To reduce mortality from gastric cancer, a high participation rate of the target population is required. The screening interval of endoscopic screening can be changed if the individual risks for UMIN000025839 (University Hospital Medical Information Network, Japan).

Sections du résumé

BACKGROUND BACKGROUND
The Japanese government has recommended a 2-year endoscopic screening interval for gastric cancer. However, insufficient resources have constrained participation in endoscopic screening for gastric cancer. One way to avoid endoscopic screening harms and provide equal access is to define the appropriate screening interval.
METHODS METHODS
To expand screening interval from more than 2 years for low-risk group, a single-arm cohort of endoscopic screening started. At the baseline screening, the participants underwent endoscopic screening for gastric cancer,
DISCUSSION CONCLUSIONS
To reduce mortality from gastric cancer, a high participation rate of the target population is required. The screening interval of endoscopic screening can be changed if the individual risks for
TRIAL REGISTRATION BACKGROUND
UMIN000025839 (University Hospital Medical Information Network, Japan).

Identifiants

pubmed: 33437803
doi: 10.21037/atm-20-5949
pii: atm-08-23-1604
pmc: PMC7791261
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1604

Informations de copyright

2020 Annals of Translational Medicine. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-5949). The authors have no conflicts of interest to declare.

Références

Cancer Med. 2016 Sep;5(9):2615-22
pubmed: 27367362
Lancet Oncol. 2011 Jul;12(7):663-72
pubmed: 21684207
Thorax. 2017 Sep;72(9):819-824
pubmed: 28360223
BMJ Open. 2019 Sep 20;9(9):e026002
pubmed: 31542733
Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(7):405-14
pubmed: 21785258
BMJ. 2014 May 20;348:g3174
pubmed: 24846275
Asian Pac J Cancer Prev. 2011;12(3):725-30
pubmed: 21627372
BMC Cancer. 2016 Nov 28;16(1):922
pubmed: 27894291
PLoS One. 2014 Oct 14;9(10):e109783
pubmed: 25314140
Am J Gastroenterol. 2019 Jan;114(1):71-79
pubmed: 30315306
Helicobacter. 2018 Aug;23(4):e12503
pubmed: 29924436
Jpn J Clin Oncol. 2016 Nov 1;46(11):1053-1061
pubmed: 27589938
Jpn J Clin Oncol. 2018 Jul 1;48(7):673-683
pubmed: 29889263
Cancer Sci. 2017 Jan;108(1):101-107
pubmed: 27727490
BMC Cancer. 2017 Mar 9;17(1):183
pubmed: 28279154
Int J Cancer. 2014 Mar 15;134(6):1445-57
pubmed: 24009139
Int J Technol Assess Health Care. 1994 Summer;10(3):346-58
pubmed: 8070998
Gut. 2013 May;62(5):676-82
pubmed: 22698649
Cancer Res. 1992 Dec 15;52(24):6735-40
pubmed: 1458460
Jpn J Clin Oncol. 2018 Mar 1;48(3):278-286
pubmed: 29315389
JAMA. 2018 Aug 21;320(7):674-686
pubmed: 30140884
World J Gastroenterol. 2018 May 28;24(20):2163-2172
pubmed: 29853734
World J Gastrointest Endosc. 2017 Feb 16;9(2):55-60
pubmed: 28250897
Gut. 2017 Feb;66(2):293-300
pubmed: 26515543

Auteurs

Chisato Hamashima (C)

Health Policy Section, Department of Nursing, Faculty of Medical Technology, Teikyo University, Tokyo, Japan.

Kenichi Yoshimura (K)

Future Medical Center, Hiroshima University Hospital, Hiroshima 734-8551, Japan.

Akira Fukao (A)

Miyagi Cancer Association, Sendai, Japan.

Classifications MeSH